Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.98EUR
25 Jul 2014
Price Change (% chg)

€-1.34 (-1.73%)
Prev Close
€77.32
Open
€77.19
Day's High
€77.27
Day's Low
€75.63
Volume
1,916,866
Avg. Vol
2,278,547
52-wk High
€80.74
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.54
Market Cap (Mil.): €102,264.60
Shares Outstanding (Mil.): 1,322.62
Dividend: 2.80
Yield (%): 3.62

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.31 35.80 36.21
EPS (TTM): 2.83 -- --
ROI: -- 18.99 18.26
ROE: -- 19.76 19.13
Search Stocks

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

16 Jul 2014

India caps price of 108 more medicines; drugmakers to take hit

MUMBAI - India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

UPDATE 1-India caps price of 108 more medicines; drugmakers to take hit

* Move aimed towards making drugs more affordable in India

14 Jul 2014

India caps prices of 108 more medicines; drugmakers to take hit

MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease. | Video

11 Jul 2014

RPT-Sanofi dengue vaccine promising but questions remain

(Repeats with no change to text to reach more subscribers)

11 Jul 2014

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

11 Jul 2014

Regeneron drug tames eczema in study

PARIS/NEW YORK - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the companies said on Wednesday.

10 Jul 2014

Sanofi-Regeneron drug tames eczema in study

PARIS/NEW YORK - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the companies said on Wednesday.

10 Jul 2014

Earnings vs. Estimates

Search Stocks